Anticariogenic Effect of Moringa Oleifera Mouthwash Compared to Chlorhexidine Mouthwash
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04575948 |
|
Recruitment Status :
Not yet recruiting
First Posted : October 5, 2020
Last Update Posted : December 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Moringa oleifera (MO) is an extraordinary nutritious vegetable tree with high medicinal value for its antibacterial properties. Formulation of various natural dental remedies from this plant and their testing for their effectiveness might yield promising antibacterial, antiplaque and anticariogenic agents with minimal side effects.
Aim of the study:
Part I: The aim of this in-vitro part of the study is to formulate a nontoxic mouthwash from MO leaves extract, having antimicrobial activity, to be used in part II of the study. Furthermore, stability and efficacy of the developed mouth wash will be evaluated.
Part II: The aim of this randomized controlled trial is to evaluate the antibacterial, antiplaque and anticariogenic effect of MO mouthwash compared to chlorhexidine mouthwash.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Plaque, Dental Antimicrobial Mouthwash Cytotoxicity | Drug: Moringa Oleifera Drug: Chlorhexidine mouthwash Drug: Base formula | Phase 2 Phase 3 |
Statement of the problem: Oral diseases remain a major health problem all over the world. Periodontal diseases and dental caries are the most common non-communicable oral diseases in mankind and the leading cause of tooth loss. Both diseases can lead to nutritional compromise and negative impact on self-esteem and quality of life. As the International situation is now changing towards the use of non- toxic and environmentally friendly products, development of modern drugs from traditional medicinal plants should be emphasized for the control of various human diseases. Moringa oleifera (MO) is an extraordinary nutritious vegetable tree with high medicinal value for its antibacterial properties. Formulation of various natural dental remedies from this plant and their testing for their effectiveness might yield promising antibacterial, antiplaque and anticariogenic agents with minimal side effects.
Aim of the study:
Part I: The aim of this in-vitro part of the study is to formulate a nontoxic mouthwash from MO leaves extract, having antimicrobial activity, to be used in part II of the study. Furthermore, stability and efficacy of the developed mouth wash will be evaluated.
Part II: The aim of this randomized controlled trial is to evaluate the antibacterial, antiplaque and anticariogenic effect of MO mouthwash compared to chlorhexidine mouthwash.
Materials and Methods:
Part I: In this part of the study; MO leaves will be extracted using different solvents. The active constituents in the form of total phenolic content (TPC) and total flavonoid content (TFC) of the developed extract will be assayed. All the prepared extracts will be evaluated for their antibacterial activity against S. mutans and P. gingivalis. The MO extract(s), which have the highest antibacterial activity will be tested for the cytotoxicity effect on gingival fibroblast cells using cell culture facilities and MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] assay. The MO mouth wash will be prepared after determination of the minimum inhibitory concentration (MIC) for the extract with the highest antibacterial activity and non-cytotoxic effect. Eventually stability and efficacy of the developed mouth wash will be tested under different storage conditions.
Part II: A triple-blind, parallel arm, randomized controlled clinical trial involving 90 patients with biofilm-induced gingivitis (plaque-induced gingivitis) and moderate-high caries risk will be carried out. Patients will be divided equally into three groups and will receive either the base formula mouthwash (BF; negative control), MO incorporated into the base formula mouthwash or commercial 0.12% Chlorhexidine HCL mouthwash (Hexitol®, H; positive control). After professional oral prophylaxis (scaling and polishing), clinical parameters measurement (gingival index, plaque index, modified sulcular bleeding index, stain index) will be determined for the project. Unstimulated saliva and plaque samples for Streptococcus mutans colony forming units (CFU) will be collected at baseline, 7th, 14th and 21st days. Salivary flow, salivary pH and International Caries Detection and Assessment System II (ICDAS II), will be recorded at baseline, 21st day, 3 months and 6 months.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 90 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Care Provider) |
| Masking Description: | Masking of all caregivers, examiners (I) and (II), as well as patients are planned. No one other than HSE at the NRC will know which mouthwash is in each bottle. HSE will not be involved in patient recruitment, follow-up or assessment |
| Primary Purpose: | Prevention |
| Official Title: | Antibacterial, Antiplaque and Anticariogenic Effect of Moringa Oleifera Mouthwash Compared to Chlorhexidine Mouthwash: A Randomized Clinical Trial |
| Estimated Study Start Date : | February 2022 |
| Estimated Primary Completion Date : | November 2022 |
| Estimated Study Completion Date : | December 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Moringa Oleifera mouth wash
According to part I of the study, we will select the most effective (Non-toxic, anti-bacterial effect) Moringa extract to prepare the mouth wash.
|
Drug: Moringa Oleifera
Non toxic Moringa extract with antibacterial and antiplaque effect will be used |
|
Placebo Comparator: Base formula of mouth wash
Base formula of mouthwash
|
Drug: Base formula
Base formula is a negative control |
|
Active Comparator: Chlorhexidine
Commercial 0.12% chlorhexidine digluconate mouthwash
|
Drug: Chlorhexidine mouthwash
Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
Other Name: Hexitol |
- Gingival index (GI) [ Time Frame: 21 days ]as assessed by Lӧe and Silness: Score from 0 to 3, Zero is normal subject
- White Spot Lesions [ Time Frame: 21 days ]Assessed by ICDAS II: Scores from 0 to 9: Zero is unrestored or unsealed tooth surface
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Systemically free as reported by the patients
- Minimum of 20 teeth present in the dentition (excluding wisdom teeth);
- Clinically healthy gingiva (on intact periodontium)
- Dental biofilm-induced gingivitis (plaque induced gingivitis) according to the criteria set by the American Academy of Periodontology for classification of periodontal diseases and conditions in 2017
- Moderate to high caries risk patients
Exclusion Criteria:
- Patients with periodontitis or requiring other immediate dental treatments (within the current 6 months)
- Subjects on antibiotics within last 6 months
- Periodontal therapy for the past 6 months
- Pregnant women and lactating mothers
- Medically compromised patients
- Subjects with tobacco consumption in any form
- Subjects wearing partial dentures or having clinically unacceptable restorations or bridges
- Subjects wearing orthodontic appliances
- History of allergy to chemical or any herbal products
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04575948
| Contact: Mahassen M Farghaly, Professor | 01111230345 | mahassen.farghaly@miuegypt.edu.eg | |
| Contact: Shahinaz G Elashiry, Assoc Prof | 01015046065 | shahinaz.elashiry@miuegypt.edu.eg |
| Study Chair: | Mahassen M Farghaly, Professor | Vice president of community services and environmental awareness |
| Responsible Party: | Misr International University |
| ClinicalTrials.gov Identifier: | NCT04575948 |
| Other Study ID Numbers: |
PER8273010 |
| First Posted: | October 5, 2020 Key Record Dates |
| Last Update Posted: | December 28, 2021 |
| Last Verified: | November 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Moringa Oleifera antibacterial activity mouthwash chlorhexidine |
antiplaque herbal translational research |
|
Dental Plaque Dental Deposits Tooth Diseases Stomatognathic Diseases |
Chlorhexidine Anti-Infective Agents, Local Anti-Infective Agents Disinfectants |